Esperion Therapeutics (NASDAQ: ESPR) reported Q2 EPS of ($0.46), $0.15 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $25.79 million versus the consensus estimate of $24.64 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.